VGI Health Technology Limited



ABN: 35 111 082 485

Address: Level 57, MLC Centre, 25 Martin Place, Sydney NSW 2000

www.vgiht.com | Tel: +61 2 8279 8908

VGI Health Technology Limited executes Deed of Settlement and Agreement with Cornwalls Lawyers Melbourne

Sydney, New South Wales, 16 September 2024 – As previously announced on 14 August 2024, VGI Health Technology Limited (VTL) was served with a creditor's statutory demand (CSD) from Cornwalls Lawyers (Cornwalls) in Melbourne (ABN 19 738 311 557, Level 4, 380 Collins Street Melbourne Victoria 3000) on 13 August 2024 and VTL had instructed its lawyers to prepare an application to court to set aside this CSD.

VTL and Cornwalls have now come to a resolution on this dispute and the parties have executed a Deed of Settlement and Agreement on 16 September 2024. The terms and conditions of this Deed are confidential however VTL is pleased to report that issues arising from the CSD have been settled.

This announcement was authorised for release by the Board of the Company.

For more information please contact:

Glenn Tong, CEO and Managing Director

Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary

Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: https://www.vgiht.com

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp